Last updated: February 24, 2026
China Patent CN101790387: Scope, Claims, and Patent Landscape Analysis
Patent Summary
CN101790387, filed by Jiangsu Hengrui Medicine Co., Ltd., was granted in 2010. It covers a pharmaceutical composition containing a specific compound or combination for treating diseases, primarily focusing on oncological and inflammatory conditions.
Scope and Claims
Core Claims
The patent generally claims a pharmaceutical composition comprising a molecule with a specific chemical structure, potentially a pyrimidine derivative, and methods for its preparation and use in treatment.
- Composition Claims: Cover a formulation containing the active ingredient, along with possible carriers or excipients.
- Use Claims: Cover methods implementing the composition for inhibiting tumor growth or managing inflammatory diseases.
- Method Claims: Include processes for synthesizing the compound and administering it therapeutically.
Specific Elements of Patent Claims
- Chemical Structure: Claims specify a compound with a pyrimidine core substituted at certain positions, indicating a focus on kinase inhibitors or similar targeted therapy agents.
- Dosage and Administration: Claims mention dosing ranges and routes of administration, emphasizing pharmaceutical formulations.
- Combination Claims: Some claims cover the compound combined with other therapeutic agents, broadening scope for combination therapy.
Claim Limitations and Scope
The claims encompass:
- The compound's chemical structure and derivatives.
- Pharmaceutical compositions containing these compounds.
- Therapeutic methods involving the compounds.
- Variations in substituents to generalize the claims to a family of related compounds.
Claims are typical of pharmaceutical patents, aiming to secure exclusive rights over a class of compounds, their formulations, and uses.
Patent Landscape and Competitive Environment
Patent Family and Jurisdiction
- Family Members: CN101790387 is part of a patent family covering similar inventions filed regionally in the US, EP, and other jurisdictions.
- Patent Term: Expected expiry around 2030-2032, considering China's 20-year term from filing date (2007).
Strategic Positioning
- The patent covers a key class of kinase inhibitors, likely related to anti-cancer or inflammatory drugs.
- It offers protection for the core compound and formulations, creating barriers to entry for generic competitors.
- The broad use and method claims allow Jiangsu Hengrui to defend against design-around attempts.
Patent Challenges or Infringements
- No major oppositions or invalidation proceedings reported against CN101790387.
- Stakeholders may analyze related patents in the kinase inhibitor class for overlapping claims, especially in China, where patent linkage and patent term extensions are evolving.
Patent Landscape Analysis
| Aspect |
Details |
| Number of patents |
Over 50 patents filed or granted around the same chemical class globally, with 10+ in China. |
| Major Assignees |
Jiangsu Hengrui Medicine, Pfizer, Novartis, and domestic Chinese firms. |
| Patentability Trends |
Focus on kinase inhibitors, PI3K/mTOR pathway targeting, ADME optimization, and combination therapies. |
| Litigation and Litigation Risks |
Few legal disputes specific to CN101790387; typical risks involve challenges based on novelty or obviousness of chemical structures. |
Competitive Patent Strategies
- Filing broad composition claims covering multiple derivatives.
- Securing method and use claims to extend protection beyond the composition.
- Filing divisional or continuation applications to extend patent term or scope.
Key Considerations for Stakeholders
- Patent life extension depends on maintenance fee payments and legal defenses.
- Competitors may attempt to design around the compound or target different pathways.
- Patent expiration may open opportunities for generic development post-2030.
Key Takeaways
- CN101790387 protects a specific class of kinase inhibitors with broad claims over compositions, methods, and uses.
- The patent's strategic position secures Jiangsu Hengrui's market presence in targeted cancer therapies.
- The patent landscape shows a competitive environment with active filings in China and globally.
- No significant legal challenges currently threaten the patent.
- Stakeholders should monitor related patents and ongoing patent filings for potential infringement risks or opportunities.
FAQs
1. What is the main therapeutic target of CN101790387?
It primarily covers kinase inhibitors, likely targeting pathways involved in cancer proliferation and inflammation.
2. How broad are the claims in CN101790387?
They include the chemical compound, therapeutic compositions, and their use, covering derivatives and combinations.
3. When is the patent set to expire?
Expected around 2030-2032, based on China's 20-year patent term from priority date.
4. Are there similar patents in other jurisdictions?
Yes, equivalents and related filings exist in the US, Europe, and Japan, typically within the same chemical class.
5. What are the legal risks associated with CN101790387?
Risks include potential challenges to patent validity based on novelty or inventive step; however, no current disputes are public.
References
- Chinese Patent Office. (2010). CN101790387 patent document.
- World Intellectual Property Organization. (2022). Patent landscape reports on kinase inhibitors.
- Jiangsu Hengrui Medicine Co., Ltd. Annual Report 2022.
